Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

saxagliptin

- PMLiVE

Lilly to acquire AtaiBeckley in deal worth $2.8bn

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

- PMLiVE

AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

The company will gain a novel oral treatment for lung cancer

- PMLiVE

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

- PMLiVE

Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis

This is the first treatment breakthrough in pulmonary fibrosis in over a decade

- PMLiVE

Teva submits FDA application for paediatric Tourette syndrome therapy

Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim

The collaboration began in 2013 and was later expanded in 2020 and 2023

- PMLiVE

Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA

Globally, around 150 to 200 out of every million people have myasthenia gravis

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly and UNICEF collaborate to improve non-communicable disease prevention

Six-year initiative to improve NCD prevention and care for children in low- and middle-income countries

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links